• HOB® Biotech will market Lisa Tracker® in China and in Asia
  • This agreement is a cross-distribution and development agreement between two leaders in Auto-immunity, Allergy and biotherapy monitoring
  • HOB® Biotech is  China’s market leader in allergy and autoimmunity in vitro diagnostics

Croissy-Beaubourg and Suzhou: 18 November, 2015 – Theradiag and HOB Diagnostics announced today they have initiated the commercialization in Asia of LISA TRACKER®, Theradiag’s flagship biotherapy monitoring kits, by entering into a mutual distribution and development agreement with the HOB® Biotech Group (“HOB”). Theradiag (ISIN: FR0004197747, Ticker: ALTER) is a company specializing in theranostics and in vitro diagnostics. With this partnership, Theradiag is also gaining access to the highly-innovative and affordable allergy and auto-immunity IVD tests developed by HOB, which it will distribute in Europe.

HOB to register, promote and distribute LISA TRACKER in Asia

“Theradiag is the first diagnostics company of its size to have established a mutual and comprehensive partnership agreement with China. With this partnership and the one signed with its US partner, MIRACA LS, Theradiag expand its distribution of Lisa Tracker® monitoring tests to Asia and the USA. HOB Biotech is a recognized leader in Auto-immunity in China; we could not think of a better partner to distribute LISA TRACKER®, our leading biotherapy monitoring range. We are equally proud to become their distribution hub in Europe. This is a historical partnership agreement which will reinforce Theradiag on its markets, and a potential game-changer for our company” commented Michel Finance, CEO of Theradiag. “The growth potential of this cross‑distribution agreement is immense, given its implication for diagnostics and theranostics sales and the size of the Asian market”.

HOB is China’s market leader in allergy and autoimmune in vitro diagnostic. With 20 years of experience in the distribution and development of high-quality immunoassays, HOB has developed a strong network of laboratory and hospital clients throughout Asia.

Under the terms of the cross-distribution agreement, HOB will proceed with the registration of LISA TRACKER® with Chinese authorities and become its exclusive distributor in China and Asia. It is estimated today that around 70 million people suffer from auto-immune diseases in China. The Chinese market for anti-TNFs biotherapies is expected to grow exponentially in the coming years as new biotherapies and biosimilars reach the market.

Companies commit to Research & Development projects for future products on innovative technology

The companies have also agreed to initiate common R&D projects to develop new allergy, autoimmunity and monitoring solutions on a new innovative technology platform, sharing experience and expertise in their respective fields. These research projects will be initiated immediately, with potential to reach the market as early as 2017.

Theradiag to become European hub of all HOB’s innovative auto-immunity and allergy IVD products

Theradiag will become HOB’s exclusive distributor in the major European countries for its innovative allergy and auto-immunity immunoassays. Today, allergy and auto-immunity currently make up 45% of Theradiag’s sales. Given the high quality and competitive prices of HOB’s allergy and autoimmunity products, Theradiag estimates that the market for these new ranges in Europe could reach the same level of sales as the expected future sales of theranostics and so generating in the next years a substantial growth of its current IVD sales.

John Li, CEO of HOB, comments: “Gaining access to the European market is of paramount importance for a company like HOB. We are looking forward to working with Theradiag to provide leading European laboratories with high-quality immunoassays at a competitive price compared to the products available in Europe which represents a strong market opportunity”.

 

About HOB Biotech Group

HOB Biotech Group is one of China’s best IVD companies. It focuses on immunoassay. HOB is China’s market leader in allergy and autoimmune in vitro diagnostics. With strong R&D capability and high quality manufacturing operation, our mission is to provide high quality products at very competitive prices to customers worldwide, while keeping our market leader position in China. HOB has an R&D team of more than 50 people, led by world class scientists trained in the USA. Our ISO13485 certified 5,000 square meter manufacturing facility is one of the best of the industry in China. The company was founded in 1996 as a distributor for USA/Europe imported products. It then got into manufacturing and R&D, making products at the same high quality standards as USA/Europe made products. HOB has achieved fast growth with its national sales coverage in the fast growing China market. Now we are expanding our business internationally, utilizing our high-quality manufacturing at competitive prices and strong R&D capabilities.

 

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

www.theradiag.com

Theradiag

Investor Relations

Fabienne François

CFO

+33 1 64 62 10 12

contact@theradiag.com

 

 NewCap

Financial communications/ investor relations

Valentine Brouchot/

Pierre Laurent

+33 1 44 71 94 94

theradiag@newcap.fr

 

Alize RP

Press

Caroline Carmagnol/
Florence Portejoie

+33 1 44 54 36 64

theradiag@alizerp.com